U.S. markets close in 1 hour 13 minutes
  • S&P 500

    3,785.67
    -5.26 (-0.14%)
     
  • Dow 30

    30,309.42
    -6.90 (-0.02%)
     
  • Nasdaq

    11,134.83
    -41.57 (-0.37%)
     
  • Russell 2000

    1,757.47
    -18.30 (-1.03%)
     
  • Crude Oil

    87.74
    +1.22 (+1.41%)
     
  • Gold

    1,724.40
    -6.10 (-0.35%)
     
  • Silver

    20.67
    -0.42 (-2.01%)
     
  • EUR/USD

    0.9889
    -0.0097 (-0.97%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • GBP/USD

    1.1339
    -0.0136 (-1.18%)
     
  • USD/JPY

    144.5020
    +0.3030 (+0.21%)
     
  • BTC-USD

    20,177.27
    +121.74 (+0.61%)
     
  • CMC Crypto 200

    457.24
    -1.17 (-0.25%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

JTC Team to Host Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Featuring CNS Pharmaceuticals

·2 min read

Live moderated video webcast with management Management to discuss potentially pivotal global study of lead asset, Berubicin, on Wednesday, September 28th at 1:00 PM ET

FRENCHTOWN, NJ / ACCESSWIRE / September 23, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) Event on Wednesday, September 28, 2022 at 1:00 PM ET. Access the event here.

JTC Team, LLC, Friday, September 23, 2022, Press release picture
JTC Team, LLC, Friday, September 23, 2022, Press release picture

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions. The Company will answer as many questions as possible during the event.

A live video webcast of the Virtual Investor Innovations in Oncology featuring CNS Pharmaceuticals will be available on virtualinvestorco.com. A webcast replay will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

Contact:

Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com

SOURCE: JTC Team, LLC



View source version on accesswire.com:
https://www.accesswire.com/717218/JTC-Team-to-Host-Virtual-Investor-Innovations-in-Oncology--Ongoing-Pivotal-Global-Study-for-Treatment-of-Glioblastoma-Multiforme-GBM-Featuring-CNS-Pharmaceuticals